Hypothesis

IL-11 directly primes the NLRP3 inflammasome in aged immune cells through a STAT3‑TXNIP axis, creating a synergistic loop with TLR4‑NF‑κB signaling that accelerates immunosenescence.

Mechanistic rationale

1. IL‑11 elevation with age – circulating IL‑11 rises in older humans and mice, acting via the IL‑11R/gp130 complex to activate STAT3 (4).
2. STAT3‑dependent TXNIP induction – STAT3 binds the promoter of thioredoxin‑interacting protein (TXNIP), a known NLRP3 activator that links oxidative stress to inflammasome assembly (2).
3. TXNIP‑mediated NLRP3 priming – increased TXNIP promotes NLRP3 oligomerization and caspase‑1 activation, independent of the canonical TLR4‑NF‑κB priming step, thereby lowering the threshold for inflammasome firing.
4. Feed‑forward amplification – NLRP3‑derived IL‑1β/IL‑18 further stimulates IL‑11 production from stromal and epithelial cells, establishing a self‑reinforcing circuit that exacerbates thymic atrophy and skews T‑cell differentiation toward proinflammatory phenotypes.

Testable predictions

• In vitro: Aged human peripheral blood mononuclear cells (PBMCs) treated with recombinant IL‑11 will show increased STAT3 phosphorylation, TXNIP mRNA/protein, and NLRP3‑dependent caspase‑1 activity compared with untreated controls; neutralization of IL‑11R or STAT3 knock‑down will abolish these effects.
• Ex vivo: Thymic slices from old mice cultured with IL‑11R antibody will exhibit reduced TXNIP expression, lower NLRP3 speck formation, and higher numbers of cortical thymic epithelial cells and naïve CD4⁺CD8⁻ T cells.
• In vivo: Administration of an IL‑11R blocking antibody (or antisense oligonucleotide) to aged mice, either alone or combined with the NLRP3 inhibitor MCC950, will (a) decrease thymic TXNIP and NLRP3 activation markers, (b) increase naïve T‑cell output and TCR diversity, and (c) improve vaccine‑induced responses more effectively than either monotherapy.
• Human correlation: Serum IL‑11 levels will positively correlate with circulating TXNIP‑positive monocytes and inversely with naïve T‑cell frequency in a cross‑sectional cohort of individuals aged 60‑80 y.

Falsifiability

If IL‑11 blockade fails to reduce TXNIP expression or NLRP3 activation in aged immune cells, or if combined IL‑11R and NLRP3 inhibition does not produce additive improvements in thymic architecture or T‑cell reconstitution beyond monotherapy, the hypothesis would be refuted.

Potential impact

Demonstrating that an IL‑6 family cytokine directly fuels NLRP3 inflammasome activity would reposition IL-11 as a upstream driver of inflammaging, justify combined cytokine‑inflammasome therapeutics for immune rejuvenation, and explain why IL‑6–targeted strategies alone have shown limited efficacy in reversing age‑related immune decline.